Name: Imsidolimab in Generalized pustular psoriasis: Natural history, survival, and mortality
Published: 2026-09-14T15:39:06-04:00

Product information and disease description Place of product in therapy Disease description

Natural history, survival, and mortality

6 evidence topics · 6 sources

National Psoriasis Foundation consensus: acuity of flares and causes of death

“GPP is a life-threatening disease that needs to be treated as quickly as possible.” (opens the source at this quote in a new tab)
“Acute flares of GPP can be life-threatening, with one-half of patients requiring hospitalization and a mortality rate of approximately 3 deaths per 100 patient years.” (opens the source at this quote in a new tab)
“most common causes of mortality include sepsis and multiorgan failure. Patients receiving biologics have lower in-hospital mortality than those receiving oral agents or corticosteroids alone.” (opens the source at this quote in a new tab)

France survival

“Twelve-month survival was 86.9% (GPP), 97.5% (plaque psoriasis), and 90.0% (the general population).” (opens the source at this quote in a new tab)

Flare recurrence

“150 patients with a baseline flare were included in this analysis” (opens the source at this quote in a new tab)
“27.3% (n=41) experienced flare recurrence during the follow-up period (mean duration: 4.16 years).” (opens the source at this quote in a new tab)

Five-year mortality

“GPP patients had higher 5-year mortality than PV (HR, 1.83; 95% CI, 1.28–2.59)” (opens the source at this quote in a new tab)

United States mortality claims analysis

“Patients with GPP exhibited an elevated mortality risk in comparison to the matched plaque-PsO and general population cohorts.” (opens the source at this quote in a new tab)

Mortality systematic review and meta-analysis

“All-cause mortality was 1.78 times higher (95% confidence interval [CI]: 1.52–2.09; P < 0.0001) for GPP than for plaque psoriasis” (opens the source at this quote in a new tab)